Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the timing of adding additional sites to the Phase III trial, the timing of completion of the enrollment of all trial subjects who will participate in the Phase III trial, the timing of the receipt of the top-line results from the double-blind portion of the Phase III trial, whether any of the Company's product candidates will ever be approved for commercialization, and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CONTACT: For Further Information Contact: Patrick J. McEnany Catalyst Pharmaceutical Partners Chief Executive Officer (305) 529-2522 firstname.lastname@example.org Melody Carey Rx Communications Group Co-President (917) 322-2571 email@example.com